Glen Weiss to Time Factors
This is a "connection" page, showing publications Glen Weiss has written about Time Factors.
Connection Strength
0.144
-
Caldwell S, Sima C, Jameson G, Fleck S, Weiss GJ. Factors influencing time to determination of the recommended phase 2 dose in phase 1 clinical trials. Am J Clin Oncol. 2013 Apr; 36(2):146-50.
Score: 0.057
-
Paripati A, Kingsley C, Weiss GJ. Pathway targets to explore in the treatment of small cell and large cell lung cancers. J Thorac Oncol. 2009 Nov; 4(11):1313-21.
Score: 0.045
-
Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389.
Score: 0.023
-
Markman M, Kramer K, Alvarez RH, Weiss GJ, Ahn E, Daneker GW. Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. Oncology. 2016; 91(6):299-301.
Score: 0.018